Loading organizations...
Medical device company developing cardiac ablation systems using Coherent Sine-burst Electroporation for atrial fibrillation treatment.
Argá Medtech is a clinical-stage medical device company based in Epalinges, Switzerland, and San Diego, California, that develops next-generation cardiac ablation systems for the treatment of atrial fibrillation and other cardiac arrhythmias. The organization utilizes a proprietary pulsed field ablation technology called Coherent Sine-Burst Electroporation to target heart tissue using a unique power generator and specialized catheter. The pre-revenue company has raised over €54 million in total venture capital funding to date. This financing includes an oversubscribed Series B round backed by institutional investors such as Gilde Healthcare, Advent Life Sciences, Earlybird Health, and BioMedPartners. The capital is currently being utilized to advance clinical trials, including an Investigational Device Exemption study in the United States and a CE Mark study in the European Union. Argá Medtech was founded in 2020 by David Neale and Randy Werneth.
Argá Medtech has raised $58.6M across 1 funding round.
Argá Medtech has raised $58.6M in total across 1 funding round.
Argá Medtech has raised $58.6M in total across 1 funding round.
Argá Medtech's investors include Advent Life Sciences, Earlybird Venture Capital.
Argá Medtech has raised $58.6M across 1 funding round. Most recently, it raised $58.6M Series B in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 27, 2024 | $58.6M Series B | Advent Life Sciences, Earlybird Venture Capital |